Beam Therapeutics grants 20,000 RSUs to legal chief

Bellon Christine reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Bellon Christine reported acquisition or exercise transactions in this Form 4 filing.

Beam Therapeutics Inc. reported that Chief Legal Officer Christine Bellon received a grant of 20,000 restricted stock units (RSUs) of common stock on March 31, 2026. Each RSU equals one share and was granted at no cash cost to her.

The RSUs vest in four substantially equal annual installments on each of the first four anniversaries of the grant date, conditioned on her continued service with Beam. After this award, she holds 115,667 shares of Beam common stock directly, reflecting a routine, compensation-related equity grant rather than an open-market purchase.

Insider Trade Summary

Grant/Award: 20,000 shares

Grant/Award 1 txn

Insider Bellon Christine

Role Chief Legal Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	20,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 115,667 shares (Direct)

Footnotes (1)

1. F1. Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

Key Figures

RSUs granted: 20,000 units Grant price: $0.00 per share Shares after transaction: 115,667 shares +1 more

4 metrics

RSUs granted 20,000 units Restricted stock units granted on March 31, 2026

Grant price $0.00 per share Stock-based compensation, no cash purchase

Shares after transaction 115,667 shares Direct Beam common stock holdings following RSU grant

Vesting schedule 4 equal installments Annually on first four anniversaries of grant date

Key Terms

restricted stock units ("RSUs"), 2019 Equity Incentive Plan, vest in four substantially equal installments, contingent right to receive one share

4 terms

restricted stock units ("RSUs") financial

"Represents restricted stock units ("RSUs") granted to the Reporting Person"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

2019 Equity Incentive Plan financial

"granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan"

vest in four substantially equal installments financial

"The RSUs vest in four substantially equal installments on each of the first four anniversaries"

contingent right to receive one share financial

"Each RSU represents the contingent right to receive one share of BEAM's common stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BEAM report for Christine Bellon?

Beam Therapeutics reported that Chief Legal Officer Christine Bellon received a grant of 20,000 restricted stock units. These RSUs convert into common shares over time as they vest, representing stock-based compensation rather than an open-market purchase.

How many Beam Therapeutics (BEAM) shares does Christine Bellon hold after this grant?

Following the 20,000-unit restricted stock grant, Christine Bellon holds 115,667 Beam Therapeutics common shares directly. This figure reflects her position after the award and helps investors understand the scale of this compensation-related equity holding.

How do the 20,000 RSUs granted by BEAM to Christine Bellon vest?

The 20,000 restricted stock units vest in four substantially equal installments on the first four anniversaries of the grant date. Each vesting installment depends on Bellon’s continued service with Beam Therapeutics through the relevant anniversary date.

What does each restricted stock unit (RSU) in the BEAM grant represent?

Each restricted stock unit granted to Christine Bellon represents the contingent right to receive one share of Beam Therapeutics common stock. The shares are delivered only as units vest over time under the company’s 2019 Equity Incentive Plan.

Was cash paid for the 20,000 Beam Therapeutics RSUs granted to Christine Bellon?

No cash was paid for the 20,000 restricted stock units granted to Christine Bellon, as the Form 4 shows a price per share of $0.00. This indicates a stock-based compensation grant under Beam’s 2019 Equity Incentive Plan.

Under which plan did Beam Therapeutics grant RSUs to Christine Bellon?

Beam Therapeutics granted the 20,000 restricted stock units to Christine Bellon under its 2019 Equity Incentive Plan. This plan governs equity-based compensation awards, including RSUs that convert into common stock upon vesting over specified service periods.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/02/2026 - 05:27 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bellon Christine

(Last) (First) (Middle)

C/O BEAM THERAPEUTICS INC.,

238 MAIN STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/31/2026		A		20,000(1)	A	$0	115,667	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date.

	By: /s/ Christine Bellon	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)